Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells

References

• Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Ruhli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. J Ovarian Res. 2022;15(1):67. doi:10.1186/s13048-022-01004-1
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-2
   PubMed Web of Science ®Google Scholar
• Yang Y, Yu Y, Chen H, et al. Illuminating platinum transportation while maximizing therapeutic efficacy by gold nanoclusters via simultaneous near-infrared-I/II imaging and glutathione scavenging. ACS Nano. 2020;14(10):13536–13547. doi:10.1021/acsnano.0c05541
   PubMed Web of Science ®Google Scholar
• Flynn MJ, Ledermann JA. Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resist. 2022;5(2):424–435. doi:10.20517/cdr.2022.13
   PubMedGoogle Scholar
• Dinic J, Efferth T, Garcia-Sosa AT, et al. Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat. 2020;52:100713. doi:10.1016/j.drup.2020.100713
   PubMed Web of Science ®Google Scholar
• Huang L, Zhao L, Zhang J, et al. Antiparasitic mebendazole (MBZ) effectively overcomes cisplatin resistance in human ovarian cancer cells by inhibiting multiple cancer-associated signaling pathways. Aging. 2021;13(13):17407–17427. doi:10.18632/aging.203232
   PubMedGoogle Scholar
• Lee H, Kwon OB, Lee JE, et al. Repositioning trimebutine maleate as a cancer treatment targeting ovarian cancer stem cells. Cells. 2021;10(4). doi:10.3390/cells10040918
   Web of Science ®Google Scholar
• Oien DB, Pathoulas CL, Ray U, Thirusangu P, Kalogera E, Shridhar V. Repurposing quinacrine for treatment-refractory cancer. Semin Cancer Biol. 2021;68:21–30. doi:10.1016/j.semcancer.2019.09.021
   PubMed Web of Science ®Google Scholar
• Tang S, Shen Y, Wei X, Shen Z, Lu W, Xu J. Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer. Cell Death Dis. 2022;13(9):826. doi:10.1038/s41419-022-05257-y
   PubMed Web of Science ®Google Scholar
• Ikemura K, Hiramatsu S, Okuda M. Drug repositioning of proton pump inhibitors for enhanced efficacy and safety of cancer chemotherapy. Front Pharmacol. 2017;8:911. doi:10.3389/fphar.2017.00911
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Fais S. Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors. Expert Opin Ther Pat. 2020;30(1):15–25. doi:10.1080/13543776.2020.1704733
   PubMed Web of Science ®Google Scholar
• Ihraiz WG, Ahram M, Bardaweel SK. Proton pump inhibitors enhance chemosensitivity, promote apoptosis, and suppress migration of breast cancer cells. Acta Pharm. 2020;70(2):179–190. doi:10.2478/acph-2020-0020
   PubMed Web of Science ®Google Scholar
• Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015;6(33):35040–35050. doi:10.18632/oncotarget.5319
   PubMed Web of Science ®Google Scholar
• Su G, Chen X, Yang H. Pantoprazole promotes the sensitivity of cervical cancer cells to cisplatin by inhibiting cisplatin-induced autophagy. J Cancer Res Ther. 2022;18(2):362–369. doi:10.4103/jcrt.jcrt_968_21
   PubMed Web of Science ®Google Scholar
• Zhang B, Yang Y, Shi X, et al. Proton pump inhibitor pantoprazole abrogates Adriamycin-resistant gastric cancer cell invasiveness via suppression of Akt/GSK-beta/beta-catenin signaling and epithelial-mesenchymal transition. Cancer Lett. 2015;356(2 Pt B):704–712. doi:10.1016/j.canlet.2014.10.016
   PubMed Web of Science ®Google Scholar
• Bai Z, Ding N, Ge J, et al. Esomeprazole overcomes paclitaxel-resistance and enhances anticancer effects of paclitaxel by inducing autophagy in A549/Taxol cells. Cell Biol Int. 2021;45(1):177–187. doi:10.1002/cbin.11481
   PubMed Web of Science ®Google Scholar
• He J, Shi XY, Li ZM, et al. Proton pump inhibitors can reverse the YAP mediated paclitaxel resistance in epithelial ovarian cancer. BMC Mol Cell Biol. 2019;20(1):49. doi:10.1186/s12860-019-0227-y
   PubMed Web of Science ®Google Scholar
• Lindner K, Borchardt C, Schopp M, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res. 2014;33:73. doi:10.1186/s13046-014-0073-x
   PubMed Web of Science ®Google Scholar
• Song T, Jeon HK, Hong JE, et al. Proton pump inhibition enhances the cytotoxicity of paclitaxel in cervical cancer. Cancer Res Treat. 2017;49(3):595–606. doi:10.4143/crt.2016.034
   PubMed Web of Science ®Google Scholar
• Matsumura S, Ishikawa T, Yoshida J, et al. Proton pump inhibitors enhance the antitumor effect of chemotherapy for esophageal squamous cell carcinoma. Cancers. 2022;14(10):2395. doi:10.3390/cancers14102395
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res. 2015;34:85. doi:10.1186/s13046-015-0194-x
   PubMed Web of Science ®Google Scholar
• Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–132. doi:10.1016/j.semcancer.2019.07.009
   PubMed Web of Science ®Google Scholar
• Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol. 2019;59:147–160. doi:10.1016/j.semcancer.2019.05.012
   PubMed Web of Science ®Google Scholar
• Choi HJ, Heo JH, Park JY, et al. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer. Gynecol Oncol. 2019;153(1):135–148. doi:10.1016/j.ygyno.2019.01.012
   PubMed Web of Science ®Google Scholar
• Deng J, Bai X, Feng X, et al. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression. BMC Cancer. 2019;19(1):618. doi:10.1186/s12885-019-5824-9
   PubMedGoogle Scholar
• Lu ZN, Shi ZY, Dang YF, et al. Pantoprazole pretreatment elevates sensitivity to vincristine in drug-resistant oral epidermoid carcinoma in vitro and in vivo. Biomed Pharmacother. 2019;120:109478. doi:10.1016/j.biopha.2019.109478
   PubMed Web of Science ®Google Scholar
• Chen M, Lu J, Wei W, et al. Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1alpha signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. Onco Targets Ther. 2018;11:6705–6722. doi:10.2147/OTT.S161198
   PubMed Web of Science ®Google Scholar
• Yang Y, Liu X, Ma W, et al. Light-activatable liposomes for repetitive on-demand drug release and immunopotentiation in hypoxic tumor therapy. Biomaterials. 2021;265:120456. doi:10.1016/j.biomaterials.2020.120456
   PubMed Web of Science ®Google Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.10
   PubMed Web of Science ®Google Scholar
• De Giorgi U, Casadei C, Bergamini A, et al. Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors. Cancers. 2019;11(10):1584. doi:10.3390/cancers11101584
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Banerjee S, Pignata S. Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives. J Clin Oncol. 2019;37(27):2437–2448. doi:10.1200/JCO.19.00194
   PubMed Web of Science ®Google Scholar
• Bogani G, Lopez S, Mantiero M, et al. Immunotherapy for platinum-resistant ovarian cancer. Gynecol Oncol. 2020;158(2):484–488. doi:10.1016/j.ygyno.2020.05.681
   PubMed Web of Science ®Google Scholar
• Le Saux O, Ray-Coquard I, Labidi-Galy SI. Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 2021;77:127–143. doi:10.1016/j.semcancer.2020.08.017
   PubMed Web of Science ®Google Scholar
• Du J, Xu Q, Zhao H, et al. PI3K inhibitor 3-MA promotes the antiproliferative activity of esomeprazole in gastric cancer cells by downregulating EGFR via the PI3K/FOXO3a pathway. Biomed Pharmacother. 2022;148:112665. doi:10.1016/j.biopha.2022.112665
   PubMed Web of Science ®Google Scholar
• Ghaffarnia R, Nasrollahzadeh A, Bashash D, Nasrollahzadeh N, Mousavi SA, Ghaffari SH. Inhibition of c-Myc using 10058-F4 induces anti-tumor effects in ovarian cancer cells via regulation of FOXO target genes. Eur J Pharmacol. 2021;908:174345. doi:10.1016/j.ejphar.2021.174345
   PubMed Web of Science ®Google Scholar
• Liu H, Yue Q, He S. Amentoflavone suppresses tumor growth in ovarian cancer by modulating Skp2. Life Sci. 2017;189:96–105. doi:10.1016/j.lfs.2017.09.026
   PubMed Web of Science ®Google Scholar
• Zhan L, Zhang Y, Wang W, Song E, Fan Y, Wei B. E2F1: a promising regulator in ovarian carcinoma. Tumour Biol. 2016;37(3):2823–2831. doi:10.1007/s13277-015-4770-7
   PubMedGoogle Scholar
• Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM, Felsher DW. The MYC oncogene - The grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 2022;19(1):23–36. doi:10.1038/s41571-021-00549-2
   PubMed Web of Science ®Google Scholar
• Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer. 2008;112(7):1415–1424. doi:10.1002/cncr.23317
   PubMed Web of Science ®Google Scholar
• Wu Z, Yu Q. E2F1-mediated apoptosis as a target of cancer therapy. Curr Mol Pharmacol. 2009;2(2):149–160. doi:10.2174/1874467210902020149
   PubMedGoogle Scholar
• Hydbring P, Castell A, Larsson LG. MYC Modulation around the CDK2/p27/SKP2 Axis. Genes. 2017;8(7):174. doi:10.3390/genes8070174
   PubMed Web of Science ®Google Scholar
• Matsumura I, Tanaka H, Kanakura Y. E2F1 and c-Myc in cell growth and death. Cell Cycle. 2003;2(4):333–338. doi:10.4161/cc.2.4.428
   PubMed Web of Science ®Google Scholar
• Zhang L, Wang C. F-box protein Skp2: a novel transcriptional target of E2F. Oncogene. 2006;25(18):2615–2627. doi:10.1038/sj.onc.1209286
   PubMed Web of Science ®Google Scholar
• Dobbin ZC, Landen CN. The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14(4):8213–8227. doi:10.3390/ijms14048213
   PubMed Web of Science ®Google Scholar
• van der Ploeg P, Uittenboogaard A, Thijs A, et al. The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: a meta-analysis. Gynecol Oncol. 2021;163(2):433–444. doi:10.1016/j.ygyno.2021.07.008
   PubMed Web of Science ®Google Scholar
• Xiao Y, Yu Y, Jiang P, Li Y, Wang C, Zhang R. The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. Cell Oncol. 2020;43(4):669–680. doi:10.1007/s13402-020-00514-8
   PubMed Web of Science ®Google Scholar
• Rinne N, Christie EL, Ardasheva A, et al. Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer. Cancer Drug Resist. 2021;4(3):573–595. doi:10.20517/cdr.2021.05
   PubMedGoogle Scholar
• Jones HM, Fang Z, Sun W, et al. Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. Am J Cancer Res. 2017;7(12):2478–2490.
   PubMed Web of Science ®Google Scholar
• Mazzoletti M, Bortolin F, Brunelli L, et al. Combination of PI3K/mTOR inhibitors: antitumor activity and molecular correlates. Cancer Res. 2011;71(13):4573–4584. doi:10.1158/0008-5472.CAN-10-4322
   PubMed Web of Science ®Google Scholar
• Das S, Shukla N, Singh SS, Kushwaha S, Shrivastava R. Mechanism of interaction between autophagy and apoptosis in cancer. Apoptosis. 2021;26(9–10):512–533. doi:10.1007/s10495-021-01687-9
   PubMed Web of Science ®Google Scholar
• Sorice M. Crosstalk of Autophagy and Apoptosis. Cells. 2022;11(9):1479. doi:10.3390/cells11091479
   PubMed Web of Science ®Google Scholar
• Tilija PN, Jang WJ, Jeong CH. Role of autophagy in regulation of cancer cell death/apoptosis during anti-cancer therapy: focus on autophagy flux blockade. Arch Pharm Res. 2020;43(5):475–488. doi:10.1007/s12272-020-01239-w
   PubMed Web of Science ®Google Scholar
• Ji Y, Hu W, Jin Y, Yu H, Fang J. Liquiritigenin exerts the anti-cancer role in oral cancer via inducing autophagy-related apoptosis through PI3K/AKT/mTOR pathway inhibition in vitro and in vivo. Bioengineered. 2021;12(1):6070–6082. doi:10.1080/21655979.2021.1971501
   PubMed Web of Science ®Google Scholar
• Yang J, Pi C, Wang G. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699–707. doi:10.1016/j.biopha.2018.04.072
   PubMed Web of Science ®Google Scholar
• Liu M, Bamodu OA, Huang WC, et al. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway. Toxicol Appl Pharmacol. 2017;325:48–60. doi:10.1016/j.taap.2017.04.003
   PubMed Web of Science ®Google Scholar
• Zhou J, Jiang YY, Chen H, Wu YC, Zhang L. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway. Cell Prolif. 2020;53(2):e12739. doi:10.1111/cpr.12739
   PubMed Web of Science ®Google Scholar
• Chueca E, Apostolova N, Esplugues JV, Garcia-Gonzalez MA, Lanas A, Piazuelo E. Proton pump inhibitors display antitumor effects in barrett’s adenocarcinoma cells. Front Pharmacol. 2016;7:452. doi:10.3389/fphar.2016.00452
   PubMed Web of Science ®Google Scholar
• Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010;1:e87. doi:10.1038/cddis.2010.67
   PubMed Web of Science ®Google Scholar
• Song M, Cui M, Liu K. Therapeutic strategies to overcome cisplatin resistance in ovarian cancer. Eur J Med Chem. 2022;232:114205. doi:10.1016/j.ejmech.2022.114205
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Zarrabi A, Hushmandi K, et al. Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin resistance. Int J Mol Sci. 2020;21(11):4002. doi:10.3390/ijms21114002
   PubMed Web of Science ®Google Scholar
• Damia G, Broggini M. Platinum resistance in ovarian cancer: role of DNA repair. Cancers. 2019;11(1):119. doi:10.3390/cancers11010119
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869–1883. doi:10.1038/onc.2011.384
   PubMed Web of Science ®Google Scholar
• Huang TT, Lampert EJ, Coots C, Lee JM. Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer. Cancer Treat Rev. 2020;86:102021. doi:10.1016/j.ctrv.2020.102021
   PubMed Web of Science ®Google Scholar
• Reyes-Gonzalez JM, Armaiz-Pena GN, Mangala LS, et al. Targeting c-MYC in platinum-resistant ovarian cancer. Mol Cancer Ther. 2015;14(10):2260–2269. doi:10.1158/1535-7163.MCT-14-0801
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Sung JJ, Barkun A, et al. Safety and tolerability of high-dose intravenous esomeprazole for prevention of peptic ulcer rebleeding. Adv Ther. 2011;28(2):150–159. doi:10.1007/s12325-010-0095-5
   PubMed Web of Science ®Google Scholar
• Jankowski J, de Caestecker J, Love SB, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392(10145):400–408. doi:10.1016/S0140-6736(18)31388-6
   PubMed Web of Science ®Google Scholar